BEAM-101
spdr s&p biotech,ishares biotechnology,Beam therapeutics
['$ibb', '$xbi']
disc shares positive initial results from phase 2 beacon trial of bitopertin for epp patients at eha 2023 congress. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt